Instead of Mylan, Teva opts for Allergan's generics business (Actavis Generics), paying $40.5bn, deal value later reduced to $38.8bn
- Generic Drugs
- OTC, Consumer
- Payment Includes Stock
- Includes Contract
- Full Acquisition
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.